Who is sponsoring NCT03651323?

NCT03651323 is sponsored by Centro Medico Docente la Trinidad.

What drugs are being tested in NCT03651323?

Interventions in NCT03651323: Left atrial appendage closure with Watchman device.

What condition does NCT03651323 study?

NCT03651323 studies Atrial Fibrillation.

Is NCT03651323 still recruiting?

NCT03651323 is currently status unknown. Last updated 29 August 2018.

Last reviewed 2018-08-29 · How we verify

NCT03651323: LATINAWERICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Latin America Registry on WatchmanTM Outcomes in Real Life

Status unknown Last updated 29 August 2018

What this trial tests

trial testing Left atrial appendage closure with Watchman device in Atrial Fibrillation in 500 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
1 November 2018

1 December 2018

Quick facts

Lead sponsor	Centro Medico Docente la Trinidad
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 October 2018
Primary completion	1 November 2018
Estimated completion	1 December 2018
Sites	1 location across Venezuela

Drugs / interventions tested

Left atrial appendage closure with Watchman device

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Centro Medico Docente la Trinidad — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Left atrial appendage (LAA) occlusion with WatchmanTM has emerged as viable alternative to anticoagulation therapy in randomized controlled trials. The device has FDA approved since 2015 and the firsts Latin American cases were performed in 2012. However, there is no real world data from Latin American experience in terms of success and outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Centro Medico Docente la Trinidad trials

Trials by the same sponsor.

NCT03818048 — Inhaled Sevofluran vs Endovenous Propofol for Colonoscopy · NA · completed
NCT03713762 — Peribulbar Block: Lidocaine-bupivacaine vs Lidocaine-bupivacaine-fentanyl · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03651323 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centro Medico Docente la Trinidad
Last refreshed: 29 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03651323.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing